Clinical Trial Update: Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating oxymorphone IR oral liquid in opioid-tolerant pediatric subjects for chronic pain has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pain

Drugs mentioned

• Oxymorphone IR oral liquid (oxymorphone)

Snippet

Sponsor: Endo Pharmaceuticals | Conditions: Chronic Pain | Phase 3 | Status: WITHDRAWN